Simultaneous haploinsufficiency of Pten and Trp53 tumor suppressor genes accelerates tumorigenesis in a mouse model of prostate cancer

Differentiation

Volumn 77, Issue 1, 2009, Pages 103-111

  Couto, Suzana S ^a   Cao, Mei ^b   Duarte, Paulo C ^c   Banach Petrosky, Whitney ^d   Wang, Shunyou ^e   Romanienko, Peter ^a   Wu, Hong ^e   Cardiff, Robert D ^f   Abate Shen, Cory ^d,g   Cunha, Gerald R ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INTERNATIONAL LIVESTOCK RESEARCH INSTITUTE   (Kenya)

^d Department of Obstetrics   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

AKT; Embryonic mesenchyme; Mouse models; Pathology; Prostate cancer; Pten; Tissue recombinants; Trp53; Tumor suppressor genes

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; SEMINAL VESICLE;

ANIMALS; DISEASE MODELS, ANIMAL; HETEROZYGOTE; LOSS OF HETEROZYGOSITY; MALE; MICE; MICE, KNOCKOUT; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; RATS; TUMOR SUPPRESSOR PROTEIN P53;

MUS; RATTUS;

EID: 60849084906     PISSN: 03014681     EISSN: 14320436     Source Type: Journal    
DOI: 10.1016/j.diff.2008.09.010     Document Type: Article

References (53)

1. Banach-Petrosky W., Ouyang X., Gao H., Nader K., Ji Y., Suh N., DiPaola R.S., and Abate-Shen C. Vitamin D inhibits the formation of prostatic intraepithelial neoplasia in Nkx3.1;Pten mutant mice. Clin. Cancer Res. 12 (2006) 5895-5901
2. Bookstein R. Tumor suppressor genes in prostatic oncogenesis. J. Cell. Biochem. 19 (1994) 217-223
3. Bookstein R., MacGrogan D., Hilsenbeck S.G., Sharkey F., and Allred D.C. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res. 53 (1993) 3369-3373
4. Cairns P., Okami K., Halachmi S., Halachmi N., Esteller M., Herman J.G., Jen J., Isaacs W.B., Bova G.S., and Sidransky D. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res. 57 (1997) 4997-5000
5. Chen Z., Trotman L.C., Shaffer D., Lin H.K., Dotan Z.A., Niki M., Koutcher J.A., Scher H.I., Ludwig T., Gerald W., Cordon-Cardo C., and Pandolfi P.P. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436 (2005) 725-730
6. Chi S.G., deVere White R.W., Meyers F.J., Siders D.B., Lee F., and Gumerlock P.H. p53 in prostate cancer: frequent expressed transition mutations. J. Natl. Cancer Inst. 86 (1994) 926-933
7. Chiaverotti T., Couto S.S., Donjacour A., Mao J.H., Nagase H., Cardiff R.D., Cunha G.R., and Balmain A. Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am. J. Pathol. 172 (2008) 236-246
8. Costa-Pereira A.P., and Cotter T.G. Molecular and cellular biology of prostate cancer-the role of apoptosis as a target for therapy. Prostate Cancer Prostatic Dis. 2 (1999) 126-139
9. Cunha G.R., and Donjacour A. Mesenchymal-epithelial interactions: technical considerations. Progr. Clin. Biol. Res. 239 (1987) 273-282
10. Di Cristofano A., Pesce B., Cordon-Cardo C., and Pandolfi P.P. Pten is essential for embryonic development and tumour suppression. Nat. Genet. 19 (1998) 348-355
11. Di Cristofano A., De Acetis M., Koff A., Cordon-Cardo C., and Pandolfi P.P. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat. Genet. 27 (2001) 222-224
12. Donjacour A.A., and Cunha G.R. Induction of prostatic morphology and secretion in urothelium by seminal vesicle mesenchyme. Development (Cambridge, England) 121 (1995) 2199-2207
13. Feng Z., Zhang H., Levine A.J., and Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc. Natl. Acad. Sci. USA 102 (2005) 8204-8209
14. Freeman D.J., Li A.G., Wei G., Li H.H., Kertesz N., Lesche R., Whale A.D., Martinez-Diaz H., Rozengurt N., Cardiff R.D., Liu X., and Wu H. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell 3 (2003) 117-130
15. Gao H., Ouyang X., Banach-Petrosky W.A., Gerald W.L., Shen M.M., and Abate-Shen C. Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer. Proc. Natl. Acad. Sci. USA 103 (2006) 14477-14482
16. Gumerlock P.H., Chi S.G., Shi X.B., Voeller H.J., Jacobson J.W., Gelmann E.P., and deVere White R.W. p53 abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The Cooperative Prostate Network. J. Natl. Cancer Inst. 89 (1997) 66-71
17. Hill R., Song Y., Cardiff R.D., and Van Dyke T. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell 123 (2005) 1001-1011
18. Kim M.J., Cardiff R.D., Desai N., Banach-Petrosky W.A., Parsons R., Shen M.M., and Abate-Shen C. Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc. Natl. Acad. Sci. USA 99 (2002) 2884-2889
19. Komazawa N., Suzuki A., Sano S., Horie K., Matsuura N., Mak T.W., Nakano T., Takeda J., and Kondoh G. Tumorigenesis facilitated by Pten deficiency in the skin: evidence of p53-Pten complex formation on the initiation phase. Cancer Sci. 95 (2004) 639-643
20. Kwabi-Addo B., Giri D., Schmidt K., Podsypanina K., Parsons R., Greenberg N., and Ittmann M. Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc. Natl. Acad. Sci. USA 98 (2001) 11563-11568
21. Li D.M., and Sun H. PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc. Natl. Acad. Sci. USA 95 (1998) 15406-15411
22. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., Miliaresis C., Rodgers L., McCombie R., Bigner S.H., Giovanella B.C., Ittmann M., Tycko B., Hibshoosh H., Wigler M.H., and Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (New York, NY) 275 (1997) 1943-1947
23. Ma L., Teruya-Feldstein J., Behrendt N., Chen Z., Noda T., Hino O., Cordon-Cardo C., and Pandolfi P.P. Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression. Genes Dev 19 (2005) 1779-1786
24. Mamillapalli R., Gavrilova N., Mihaylova V.T., Tsvetkov L.M., Wu H., Zhang H., and Sun H. PTEN regulates the ubiquitin-dependent degradation of the CDK inhibitor p27(KIP1) through the ubiquitin E3 ligase SCF(SKP2). Curr. Biol. 11 (2001) 263-267
25. Mao J.H., Wu D., Perez-Losada J., Nagase H., DelRosario R., and Balmain A. Genetic interactions between Pten and p53 in radiation-induced lymphoma development. Oncogene 22 (2003) 8379-8385
26. Mayo L.D., Dixon J.E., Durden D.L., Tonks N.K., and Donner D.B. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J. Biol. Chem. 277 (2002) 5484-5489
27. Meyers F.J., Gumerlock P.H., Chi S.G., Borchers H., Deitch A.D., and deVere White R.W. Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors. Cancer 83 (1998) 2534-2539
28. Oki E., Tokunaga E., Nakamura T., Ueda N., Futatsugi M., Mashino K., Yamamoto M., Watanabe M., Ikebe M., Kakeji Y., Baba H., and Maehara Y. Genetic mutual relationship between PTEN and p53 in gastric cancer. Cancer Lett. 227 (2005) 33-38
29. Park J.H., Walls J.E., Galvez J.J., Kim M., Abate-Shen C., Shen M.M., and Cardiff R.D. Prostatic intraepithelial neoplasia in genetically engineered mice. Am. J Pathol. 161 (2002) 727-735
30. Podsypanina K., Ellenson L.H., Nemes A., Gu J., Tamura M., Yamada K.M., Cordon-Cardo C., Catoretti G., Fisher P.E., and Parsons R. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc. Natl. Acad. Sci. USA 96 (1999) 1563-1568
31. Radu A., Neubauer V., Akagi T., Hanafusa H., and Georgescu M.M. PTEN induces cell cycle arrest by decreasing the level and nuclear localization of cyclin D1. Mol. Cell. Biol. 23 (2003) 6139-6149
32. Risbridger G., Wang H., Young P., Kurita T., Wang Y.Z., Lubahn D., Gustafsson J.A., and Cunha G. Evidence that epithelial and mesenchymal estrogen receptor-alpha mediates effects of estrogen on prostatic epithelium. Dev. Biol. 229 (2001) 432-442
33. Shappell S.B., Thomas G.V., Roberts R.L., Herbert R., Ittmann M.M., Rubin M.A., Humphrey P.A., Sundberg J.P., Rozengurt N., Barrios R., Ward J.M., and Cardiff R.D. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor Meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res. 64 (2004) 2270-2305
34. Sheng X., Koul D., Liu J.L., Liu T.J., and Yung W.K. Promoter analysis of tumor suppressor gene PTEN: identification of minimum promoter region. Biochem. Biophys. Res. Commun. 292 (2002) 422-426
35. Stambolic V., Tsao M.S., Macpherson D., Suzuki A., Chapman W.B., and Mak T.W. High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice. Cancer Res. 60 (2000) 3605-3611
36. Stambolic V., MacPherson D., Sas D., Lin Y., Snow B., Jang Y., Benchimol S., and Mak T.W. Regulation of PTEN transcription by p53. Mol. Cell 8 (2001) 317-325
37. Sugimura Y., Cunha G.R., and Donjacour A.A. Morphological and histological study of castration-induced degeneration and androgen-induced regeneration in the mouse prostate. Biol. Reprod. 34 (1986) 973-983
38. Sun H., Lesche R., Li D.M., Liliental J., Zhang H., Gao J., Gavrilova N., Mueller B., Liu X., and Wu H. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc. Natl. Acad. Sci. USA 96 (1999) 6199-6204
39. Suzuki H., Freije D., Nusskern D.R., Okami K., Cairns P., Sidransky D., Isaacs W.B., and Bova G.S. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res. 58 (1998) 204-209
40. Trotman L.C., and Pandolfi P.P. PTEN and p53: who will get the upper hand?. Cancer Cell 3 (2003) 97-99
41. Trotman L.C., Niki M., Dotan Z.A., Koutcher J.A., Di Cristofano A., Xiao A., Khoo A.S., Roy-Burman P., Greenberg N.M., Van Dyke T., Cordon-Cardo C., and Pandolfi P.P. Pten dose dictates cancer progression in the prostate. PLoS Biol. 1 (2003) E59
42. Truett G.E., Heeger P., Mynatt R.L., Truett A.A., Walker J.A., and Warman M.L. Preparation of PCR-quality mouse genomic DNA with hot sodium hydroxide and tris (HotSHOT). BioTechniques 29 (2000) 52 54
43. Umbas R., Schalken J.A., Aalders T.W., Carter B.S., Karthaus H.F., Schaafsma H.E., Debruyne F.M., and Isaacs W.B. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res. 52 (1992) 5104-5109
44. Umbas R., Isaacs W.B., Bringuier P.P., Schaafsma H.E., Karthaus H.F., Oosterhof G.O., Debruyne F.M., and Schalken J.A. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res. 54 (1994) 3929-3933
45. Umbas R., Isaacs W.B., Bringuier P.P., Xue Y., Debruyne F.M., and Schalken J.A. Relation between aberrant alpha-catenin expression and loss of E-cadherin function in prostate cancer. Int. J. Cancer 74 (1997) 374-377
46. Wakabayashi Y., Mao J.H., Brown K., Girardi M., and Balmain A. Promotion of Hras-induced squamous carcinomas by a polymorphic variant of the Patched gene in FVB mice. Nature 445 (2007) 761-765
47. Wang J., Ouyang W., Li J., Wei L., Ma Q., Zhang Z., Tong Q., He J., and Huang C. Loss of tumor suppressor p53 decreases PTEN expression and enhances signaling pathways leading to activation of activator protein 1 and nuclear factor kappaB induced by UV radiation. Cancer Res. 65 (2005) 6601-6611
48. Wang S., Gao J., Lei Q., Rozengurt N., Pritchard C., Jiao J., Thomas G.V., Li G., Roy-Burman P., Nelson P.S., Liu X., and Wu H. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4 (2003) 209-221
49. Wang S., Garcia A.J., Wu M., Lawson D.A., Witte O.N., and Wu H. Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc. Natl. Acad. Sci. USA 103 (2006) 1480-1485
50. Wang S.I., Parsons R., and Ittmann M. Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. Clin. Cancer Res. 4 (1998) 811-815
51. Wang Y., Hayward S.W., Donjacour A.A., Young P., Jacks T., Sage J., Dahiya R., Cardiff R.D., Day M.L., and Cunha G.R. Sex hormone-induced carcinogenesis in Rb-deficient prostate tissue. Cancer Res. 60 (2000) 6008-6017
52. Yuan Z.Q., Sun M., Feldman R.I., Wang G., Ma X., Jiang C., Coppola D., Nicosia S.V., and Cheng J.Q. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 19 (2000) 2324-2330
53. Zheng H.C., Sun J.M., Li X.H., Yang X.F., Zhang Y.C., and Xin Y. Role of PTEN and MMP-7 expression in growth, invasion, metastasis and angiogenesis of gastric carcinoma. Pathol. Int. 53 (2003) 659-666